Literature DB >> 24776999

Central serous chorioretinopathy.

Raffael Liegl1, Michael W Ulbig.   

Abstract

The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The involvement of corticosteroids is undisputed, although their exact role has not been clarified; other parts of the underlying mechanism of CSC have been mainly elucidated by imaging techniques such as fluorescein and indocyanine green angiography. Even though most cases of CSC are self-limiting, severe as well as recurrent courses exist, and for these patients only a limited number of treatment options are available: laser photocoagulation, with a risk of scotoma and choroidal neovascularization, and photodynamic therapy. In this review article, we give an overview of its epidemiology, the current understanding of its pathogenesis as well as systemic and ocular risk factors. We illuminate modern diagnostic tools as well as current treatment options in the context of CSC, particularly in the light of a better understanding of corticosteroids and their receptors involved in its pathogenesis.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24776999     DOI: 10.1159/000360014

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  36 in total

1.  Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.

Authors:  Seoung Hyun An; Yoon Hyung Kwon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-09       Impact factor: 3.117

2.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

3.  The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.

Authors:  A Ozkaya; Z Alkin; M Ozveren; A T Yazici; M Taskapili
Journal:  Eye (Lond)       Date:  2016-04-22       Impact factor: 3.775

4.  Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).

Authors:  Tina Rike Herold; Kristina Rist; Siegfried Georg Priglinger; Michael Werner Ulbig; Armin Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-31       Impact factor: 3.117

5.  Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography.

Authors:  Jingyuan Yang; Erqian Wang; Mingzhen Yuan; Youxin Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-14       Impact factor: 3.117

6.  [Uniform classification of the pachychoroid spectrum disorders].

Authors:  Alaa Din Abdin; Shady Suffo; Fabian N Fries; Hakan Kaymak; Berthold Seitz
Journal:  Ophthalmologe       Date:  2021-04-26       Impact factor: 1.059

7.  Corticosteroids usage and central serous chorioretinopathy: a meta-analysis.

Authors:  Ge Ge; Yun Zhang; Yichi Zhang; Zhihui Xu; Meixia Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-16       Impact factor: 3.117

8.  Is the unaffected eye really unaffected? Color Doppler ultrasound findings in unilaterally active central serous chorioretinopathy.

Authors:  Iclal Erdem Toslak; Muhammet Kazim Erol; Devrim Toslak; Bulent Cekic; Mehtap Barc Ergun; Jennifer E Lim-Dunham
Journal:  J Med Ultrason (2001)       Date:  2016-12-18       Impact factor: 1.314

9.  Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.

Authors:  Bertan Cakir; Franziska Fischer; Christoph Ehlken; Anima Bühler; Andreas Stahl; Günther Schlunck; Daniel Böhringer; Hansjürgen Agostini; Clemens Lange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-05       Impact factor: 3.117

10.  Relationship between mean platelet volume and central serous chorioretinopathy.

Authors:  Ayhan Dursun; Mustafa Ilker Toker; Ayşe Vural Ozec; Erman Bozali; Kadir Kirboga; Feyza Gulac Dursun; Haydar Erdogan; Aysen Topalkara; Mustafa Kemal Arici
Journal:  Int Ophthalmol       Date:  2016-04-25       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.